EQGen Biomedical is developing a proprietary, next-generation stem cell treatment for equine osteoarthritis and musculoskeletal disease. The existing platform technology leverages a proprietary method to purify pluripotent stem cell populations with the potential to treat equine inflammatory and degenerative joint disease as a true Disease Modifying Osteoarthritis Drug (DMOAD). Future product development will utilize the same innovation for use in canines and camelids. Our mission is to deliver next-generation products in veterinary medicine and to optimize the health of animals globally.  

Osteoarthritis (OA) is a leading cause of equine lameness. As in humans, OA is a chronic degenerative disease involving the entire joint. Because cartilage has no or minimal ability for intrinsic repair, OA destruction of the cartilage cannot be reversed. The result is painful joints with crepitation, decreased range of motion and loss of performance.

Current clinical management targets symptomatic pain relief and reduction of joint inflammation. Commonly used medications, synthetic compounds, and existing allogeneic or autologous treatments are inadequate with no or limited regenerative ability.

EQGen Biomedical is developing an off-the-shelf, cost-effective stem cell product which eliminates the need for blood or tissue harvest from patients and requires no product preparation. Unlike other therapies, our solution is being engineered as a true disease modifying drug which has the potential to reverse the course of OA progression.

EQGen Biomedical, Inc.

Org chart

Teams

Offices